Literature DB >> 29016757

Association of left atrial low-voltage area and thromboembolic risk in patients with atrial fibrillation.

Patrick Müller1,2, Hisaki Makimoto2, Johannes W Dietrich3, Franzsika Fochler1, Karin Nentwich1, Joachum Krug1, David Duncker4, Christian Blockhaus2, Malte Kelm2, Alexander Fürnkranz2, Thomas Deneke1, Philipp Halbfass1.   

Abstract

Aims: Atrial fibrillation (AF) is associated with thromboembolic events. Currently, the CHA2DS2-VASc score is recommended for thromboembolic risk stratification in non-valvular AF patients. However, recent data suggested a potential role of atrial remodelling on thromboembolism. This study aimed to assess the association between left atrial low-voltage area (LVA) and history of clinical manifest as well as subclinical silent cerebral ischaemia (SCI) in AF patients. Methods and results: Two-hundred patients [64 ± 10.5 years, 75 women (37.5%)] with symptomatic paroxysmal (n = 88, 44%) or persistent AF undergoing pulmonary vein isolation (PVI) were prospectively enrolled. Left atrial LVA (bipolar voltage < 0.5mV) was evaluated by intra-procedural mapping (>300 points per patient) during sinus rhythm. Cerebral delayed-enhancement magnetic resonance imaging was performed after PVI for detection of pre-existing procedural-independent SCI. Over all, 17 patients (8.5%) had previous history of stroke. Pre-existing SCIs were detected in 135 patients (67.5%). Patients with previous stroke (4.0 ± 1.5 vs. 2.1 ± 1.3, P < 0.0001) and pre-existing SCI (2.7 ± 1.3 vs. 1.5 ± 1.4, P < 0.0001) had a significantly higher CHA2DS2-VASc score. LVA was significantly larger in patients with previous stroke (12.5 ± 8.5% vs. 3.4 ± 5.4%, P < 0.0001) as well as pre-existing SCI (5.8 ± 6.9% vs. 0.8 ± 1.7%, P < 0.0001). Multivariate regression analysis revealed that LVA was independently associated with the presence of SCI [hazard ratio (HR) per 1% LVA 1.13 (1.06-1.22), P = 0.0003] and history of stroke [HR per 1% LVA 1.36 (1.19-1.60), P < 0.0001] after adjustment of CHA2DS2-VASc score.
Conclusion: Left atrial LVA is associated with history of stroke and SCI in patients with non-valvular AF and might improve thromboembolic risk stratification after confirmation of its predictive value in future studies.

Entities:  

Mesh:

Year:  2018        PMID: 29016757     DOI: 10.1093/europace/eux172

Source DB:  PubMed          Journal:  Europace        ISSN: 1099-5129            Impact factor:   5.214


  11 in total

1.  Impact of low-voltage zones on the left atrial anterior wall on the reduction in the left atrial appendage flow velocity in persistent atrial fibrillation patients.

Authors:  Yuichi Hori; Shiro Nakahara; Naoki Nishiyama; Reiko Fukuda; Tomoaki Ukaji; Hirotsugu Sato; Yuri Koshikawa; Shu Inami; Tetsuya Ishikawa; Sayuki Kobayashi; Yoshihiko Sakai; Isao Taguchi
Journal:  J Interv Card Electrophysiol       Date:  2019-03-18       Impact factor: 1.900

Review 2.  Left Atrial Cardiomyopathy - A Challenging Diagnosis.

Authors:  Fabienne Kreimer; Michael Gotzmann
Journal:  Front Cardiovasc Med       Date:  2022-06-30

Review 3.  The Atrium in Atrial Fibrillation - A Clinical Review on How to Manage Atrial Fibrotic Substrates.

Authors:  Pedro Silva Cunha; Sérgio Laranjo; Jordi Heijman; Mário Martins Oliveira
Journal:  Front Cardiovasc Med       Date:  2022-07-04

4.  Low-Voltage Area at the Anterior Wall of the Left Atrium Is Associated With Thromboembolism in Atrial Fibrillation Patients With a Low CHA2DS2-VA Score.

Authors:  Xiangwei Ding; Mingfang Li; Hongwu Chen; Gang Yang; Fengxiang Zhang; Weizhu Ju; Kai Gu; Jianqing Li; Minglong Chen
Journal:  Front Cardiovasc Med       Date:  2022-06-13

5.  Left Atrial Hypertension, Electrical Conduction Slowing, and Mechanical Dysfunction - The Pathophysiological Triad in Atrial Fibrillation-Associated Atrial Cardiomyopathy.

Authors:  Martin Eichenlaub; Bjoern Mueller-Edenborn; Jan Minners; Nikolaus Jander; Martin Allgeier; Heiko Lehrmann; Simon Schoechlin; Juergen Allgeier; Dietmar Trenk; Franz-Josef Neumann; Thomas Arentz; Amir Jadidi
Journal:  Front Physiol       Date:  2021-08-05       Impact factor: 4.566

6.  Sex-Related Differences in Left Atrial Low-Voltage Areas According to CHA2DS2-VA Scores among Patients with Atrial Fibrillation.

Authors:  Do Young Kim; Yun Gi Kim; Ha Young Choi; Yun Young Choi; Ki Yung Boo; Kwang-No Lee; Seung-Young Roh; Jaemin Shim; Jong-Il Choi; Young-Hoon Kim
Journal:  J Clin Med       Date:  2022-05-31       Impact factor: 4.964

7.  Electrocardiographic diagnosis of atrial cardiomyopathy to predict atrial contractile dysfunction, thrombogenesis and adverse cardiovascular outcomes.

Authors:  Björn Müller-Edenborn; Jan Minners; Cornelius Keyl; Martin Eichenlaub; Nikolaus Jander; Sherif Abdelrazek; Christoph Ahlgrim; Jürgen Allgeier; Heiko Lehrmann; Franz-Josef Neumann; Thomas Arentz; Amir Jadidi
Journal:  Sci Rep       Date:  2022-01-12       Impact factor: 4.379

8.  Echocardiographic and Electrocardiographic Determinants of Atrial Cardiomyopathy Identify Patients with Atrial Fibrillation at Risk for Left Atrial Thrombogenesis.

Authors:  Taiyuan Huang; Schurr Patrick; Louisa Katharina Mayer; Björn Müller-Edenborn; Martin Eichenlaub; Martin Allgeier; Jürgen Allgeier; Heiko Lehrmann; Christoph Ahlgrim; Marius Bohnen; Simon Schoechlin; Dietmar Trenk; Nikolaus Jander; Franz Josef Neumann; Thomas Arentz; Amir Jadidi
Journal:  J Clin Med       Date:  2022-02-28       Impact factor: 4.241

9.  Isolated atrial amyloidosis suspected by electrophysiological voltage mapping and diagnosed by 99m Tc-DPD scintigraphy.

Authors:  Doreen Schöppenthau; Imke Schatka; Alexander Berger; Burkert Pieske; Kathrin Hahn; Fabian Knebel; Felix Kleefeld; Tobias Alexander; Jin-Hong Gerds-Li; Daniel Messroghli
Journal:  ESC Heart Fail       Date:  2020-10-04

10.  Echocardiographic diagnosis of atrial cardiomyopathy allows outcome prediction following pulmonary vein isolation.

Authors:  Martin Eichenlaub; Bjoern Mueller-Edenborn; Jan Minners; Martin Allgeier; Heiko Lehrmann; Juergen Allgeier; Dietmar Trenk; Franz-Josef Neumann; Nikolaus Jander; Thomas Arentz; Amir Jadidi
Journal:  Clin Res Cardiol       Date:  2021-04-29       Impact factor: 5.460

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.